First-line durvalumab plus platinum–etoposide in Japanese patients with extensive-stage small-cell lung cancer
First-line EP plus durvalumab was effective and well tolerated in Japanese patients with ES-SCLC in a real-world setting aligning with findings of global studies. This regimen should be considered the standard of care for Japanese patients with ES-SCLC.
Authors
- Naoki Inui (ORCID: https://orcid.org/0000-0002-4624-7119)
- Ryunosuke Inaba
- Eisuke Mochizuki
- Masato Karayama (ORCID: https://orcid.org/0000-0003-0455-4070)
- Masayuki Watanuki
- Sho Takuma
- Shogo Sakurai (ORCID: https://orcid.org/0000-0002-6354-5548)
- Naoki Koshimizu
- Shun Matsuura (ORCID: https://orcid.org/0000-0001-8844-6100)
- Yusuke Inoue (ORCID: https://orcid.org/0000-0001-8075-0597)
- Suguru Kojima
- Satoshi Kishimoto
- Takafumi Suda (ORCID: https://orcid.org/0000-0001-5300-0504)
- Mitsuru Niwa
Institutions
- Hamamatsu University School of Medicine (JP)
- Seirei Mikatabara General Hospital (JP)
- Iwata City Hospital (JP)
- Seirei Hamamatsu General Hospital (JP)
- Shizuoka City Hospital (JP)
- Shizuoka General Hospital (JP)
- Fujieda Municipal General Hospital (JP)
- Hamamatsu Medical Center (JP)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2025.100972
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00